Application of circulating tumor DNA in digestive system neoplasms

doi:10.3969/j.issn.1006-7795.2023.06.015

Abstract

Abstract: Circulating tumor DNA (ctDNA) is a type of circulating free DNA (cfDNA), which is released into the blood by apoptotic or necrotic tumor cells, or directly secreted by tumors. ctDNA carries tumor-specific genetic and epigenetic characteristics, including gene mutations, chromosome rearrangements, copy number variations, and methylation changes. ctDNA liquid biopsy technique has the advantages of easy operation, high repeatability and minimal invasion. ctDNA can be used to screen and diagnose early stage of digestive system tumor, guide treatment, monitor therapeutic effect, analyze postoperative residual lesions and prevent disease recurrence. This article discusses the biological characteristics, detection methods, and application of ctDNA in digestive system neoplasms.

Key words: circulating tumor DNA, circulating free DNA, liquid biopsy, digestive system neoplasms

CLC Number:

Yu Mingxin, Yang Aiming. Application of circulating tumor DNA in digestive system neoplasms[J]. Journal of Capital Medical University, 2023, 44(6): 999-1005.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.06.015

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I6/999

References

［1］王芮, 李朝燕, 赵爱光. 循环肿瘤DNA检测在胃癌诊疗中的应用现状［J］. 检验医学, 2022, 37(9): 877-881.
［2］张音洁, 王晰程. 循环肿瘤DNA在消化系统肿瘤中的临床应用［J］. 癌症进展, 2019, 17(2): 131-136.
［3］Mandel P, Metais P. Nuclear acids in human blood plasma［J］. C R Seances Soc Biol Fil, 1948, 142(3/4): 241-243.
［4］Caldas C, Hahn S A, Hruban R H, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia［J］. Cancer Res, 1994, 54(13): 3568-3573.
［5］Pessoa L S, Heringer M, Ferrer V P. ctDNA as a cancer biomarker: a broad overview［J］. Crit Rev Oncol Hematol, 2020, 155: 103109.
［6］蒋婷, 王平, 黄新恩. 液体活检在胃癌诊疗中的研究进展［J］. 医学研究杂志, 2022, 51(5): 22-25.
［7］许晶, 金顺花. 循环肿瘤DNA在消化系统肿瘤中的应用进展［J］. 医学研究生学报, 2022, 35(8): 883-888.
［8］Cui S H, Ye L, Wang H M, et al. Use of SuperARMS EGFR mutation detection kit to detect EGFR in plasma cell-free DNA of patients with lung adenocarcinoma［J］. Clin Lung Cancer, 2018, 19(3): e313-e322.
［9］Franczak C, Filhine-Tresarrieu P, Gilson P, et al. Technical considerations for circulating tumor DNA detection in oncology［J］. Expert Rev Mol Diagn, 2019, 19(2): 121-135.
［10］Postel M, Roosen A, Laurent-Puig P, et al. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective［J］. Expert Rev Mol Diagn, 2018, 18(1): 7-17.
［11］Liu K, Cui Y L, Li H, et al. The mechanism investigation of mutation genes in liver and lung metastasis of colorectal cancer by using NGS technique［J］. Crit Rev Oncol Hematol, 2023, 188: 104057.
［12］Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications［J］. J Hematol Oncol, 2022, 15(1): 131.
［13］Wardenaar R, Liu H Y, Colot V, et al. Evaluation of MeDIP-chip in the context of whole-genome bisulfite sequencing (WGBS-seq) in Arabidopsis［J］. Methods Mol Biol, 2013, 1067: 203-224.
［14］Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing［J］. Proc Natl Acad Sci U S A, 2011, 108(23): 9530-9535.
［15］Li H Z, Jing C W, Wu J Z, et al. Circulating tumor DNA detection: a potential tool for colorectal cancer management［J］. Oncol Lett, 2019, 17(2): 1409-1416.
［16］Newman A M, Bratman S V, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage［J］. Nat Med, 2014, 20(5): 548-554.
［17］Pinheiro M, Peixoto A, Rocha P, et al. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR［J］. Int J Colorectal Dis, 2022, 37(4): 895-905.
［18］Adashek J J, Janku F, Kurzrock R. Signed in blood: circulating tumor DNA in cancer diagnosis, treatment and screening［J］. Cancers (Basel), 2021, 13(14): 3600.
［19］Food and Drug Administration (FDA). Nucleic acid based tests［EB/OL］. (2023-05-26)［2023-06-28］. https://www.fda.gov/medical-devices/in-vitro-diagnostics/nucleic-acid-based-tests.
［20］国家药品监督管理局. 数据查询［DB/OL］. ［2023-06-28］. https://www.nmpa.gov.cn/datasearch/home-index.html?itemId=ff8080817c8312c4017c9bbfc8de 0360&3jfdxVGGVXFo=1698930093503category=ylqx.
［21］Lofton-Day C, Model F, Devos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening［J］. Clin Chem, 2008, 54(2): 414-423.
［22］Iyer P, Zekri A R, Hung C W, et al. Concordance of DNA methylation pattern inplasma and tumor DNA of Egyptian hepatocellular carcinoma patients［J］. Exp Mol Pathol, 2010, 88(1): 107-111.
［23］Gao J, Wang H X, Zang W C, et al. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer［J］. Cancer Sci, 2017, 108(9): 1881-1887.
［24］Clifton K, Rich T A, Parseghian C, et al. Identification of actionable fusions as an anti-EGFR resistance mechanism using a circulating tumor DNA assay［J］. JCO Precis Oncol, 2019, 3:1-15.
［25］Martini G, Ciardiello D, Famiglietti V, et al. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: individual patient data pooled analysis of CRICKET and CAVE trials［J］. Cancer Med, 2023, 12(8): 9392-9400.
［26］Chennamadhavuni A, Kasi P M. Circulating tumor DNA in identifying resistant sub-clones post EGFR blockade: implications for EGFR rechallenge［J］. Front Oncol, 2022, 12: 847299.
［27］Montagut C, Argilés G, Ciardiello F, et al. Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: a phase 2 randomized clinical trial［J］. JAMA Oncol, 2018, 4(4): e175245.
［28］Dasari A, Morris V K, Allegra C J, et al. ctDNA applications and integration in colorectal cancer: an NCI colon and rectal-anal task forces whitepaper［J］. Nat Rev Clin Oncol, 2020, 17(12): 757-770.
［29］Kim S, Sun J H, Kim H, et al. Pembrolizumab-induced psoriatic arthritis treated with disease-modifying anti-rheumatic drugs in a patient with gastric cancer: a case report［J］. World J Clin Cases, 2023, 11(1): 218-224.
［30］Xu J X, Song J J, Chen X X, et al. Genomic instability-related twelve-microRNA signatures for predicting the prognosis of gastric cancer［J］. Comput Biol Med, 2023, 155: 106598.
［31］Reinert T, Schøler L V, Thomsen R, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery［J］. Gut, 2016, 65(4): 625-634.
［32］Li J, Li Z Y, Ding Y J, et al. TP53 mutation and met amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer［J］. PeerJ, 2021, 9: e11146.
［33］Lecomte T, Berger A, Zinzindohoué F, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis［J］. Int J Cancer，2002 100(5):542-548.
［34］Peng Y, Mei W X, Ma K D, et al. Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives［J］. Front Oncol, 2021, 11: 763790.
［35］Hasenleithner S O, Speicher M R. A clinician's handbook for using ctDNA throughout the patient journey［J］. Mol Cancer, 2022, 21(1): 81.
［36］Mathios D, Johansen J S, Cristiano S, et al. Detection and characterization of lungcancer using cell-free DNA fragmentomes［J］. Nat Commun, 2021, 12(1): 5060.

[1]	Qiao Xinwei, Qiu Yuting, Li Peng, Wu Jing, Zhang Shutian. Preliminary study on risk factors of short-term adverse events after endoscopic papillectomy [J]. Journal of Capital Medical University, 2023, 44(6): 982-989.
[2]	He Zhen, Qin Da, Li Peng, Zhu Shengtao, Ji Ming, Zhang Shutian. The effect assessment of 8-like ring assisted endoscopic submucosal dissection for colorectal lesions [J]. Journal of Capital Medical University, 2023, 44(6): 973-977.
[3]	Liu Juan, Wang Wenjing, Zhao Guiping, Wang Yongjun, Li Peng, Wu Yongdong, Zhang Shutian. Risk factors associated with recurrence of achalasia after peroral endoscopic myotomy [J]. Journal of Capital Medical University, 2023, 44(6): 978-981.
[4]	Qiao Xinwei, Qiu Yuting, Li Peng, Wu Jing, Zhang Shutian. Analysis of clinical characteristics of patients with duodenal papilla neoplasms and the diagnostic value for advanced carcinoma [J]. Journal of Capital Medical University, 2023, 44(6): 990-998.
[5]	Qiao Xinwei, Qiu Yuting, Li Peng, Wu Jing, Zhang Shutian. Preliminary study on risk factors of short-term adverse events after endoscopic papillectomy [J]. Journal of Capital Medical University, 0, (): 982-989.
[6]	Wang Yadan, Wang Miaomiao, Guo Chunmei, Tai Weiping, Liu Hong, Su Hui, Wang Canghai, Wu Jing. Establishment and validation of an early prediction model for severity of acute pancreatitis [J]. Journal of Capital Medical University, 2023, 44(2): 302-310.
[7]	hi Tianyu, Zhao Quchuan. Clinical analysis of gastric xanthomas with intestinal metaplasia [J]. Journal of Capital Medical University, 2023, 44(2): 322-327.
[8]	Wang Yun, Li Wenkun, Su Jiayi, Wang Yadan, Wu Jing. Application value of systemic immune-inflammation index in the screening of early colorectal cancer and precancerous lesions [J]. Journal of Capital Medical University, 2022, 43(5): 760-766.
[9]	Liu Chuntao, Su Jiayi, Dan Zengzhuoga, Yi Biranhen, Zhuo Ma, Zhang Shutian. Correlation between Helicobacter pylori virulence strains and chronic gastritis and peptic ulcer in Tibetan population in Tibet Autonomous Region [J]. Journal of Capital Medical University, 2022, 43(3): 463-468.
[10]	Ma Mingyang, Wang Jiewei, Li Peng. Application of endocytoscopy in the valuation of colorectal lesions [J]. Journal of Capital Medical University, 2022, 43(2): 221-226.
[11]	Su Jiayi, Liu Chuntao, Wang Tieshan, Li Wenkun, Yang Yi, Wu Shanshan, Li Peng, Wu Jing. Correlation between serum Helicobacter pylori antibody typing and gastric mucosal lesions [J]. Journal of Capital Medical University, 2022, 43(2): 216-220.
[12]	Wang Rongxin, Wang Jing, Hu Shuiqing. Analysis of risk factors in patients with reflux esophagitis with extra-esophageal symptoms [J]. Journal of Capital Medical University, 2022, 43(1): 132-137.
[13]	Cheng Rui, Zhu Siying, Liu Simao, Zhou Yanhua, Zong Ye, Li Peng, Zhang Shutian. Experience in endoscopic treatment of esophageal and gastric varices with upper gastrointestinal mass [J]. Journal of Capital Medical University, 2022, 43(1): 22-27.
[14]	Li Jielin, Liu Tianyu, Zhang Shutian, Wei Yongqiu, Ji Ming, Li Peng, Wang Yongjun, Wu Yongdong. Safety evaluation of pancreatic duct stent placement through duodenal accessory papilla cannulation [J]. Journal of Capital Medical University, 2022, 43(1): 28-33.
[15]	Zhang Xinghua, Xing jie, Sun Can, Zhang Xi, Wang Yongjun. Pilot study on the mechanism of B cell chemotaxis of macrophage in ulcerative colitis [J]. Journal of Capital Medical University, 2022, 43(1): 42-46.